• Ethan Cowan, Jeanmarie Perrone, Steven L Bernstein, Edouard Coupet, David A Fiellin, Kathryn Hawk, Andrew Herring, Kristen Huntley, Ryan McCormack, Arjun Venkatesh, and Gail D'Onofrio.
• Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: ethan.cowan@mountsinai.org.
• Ann Emerg Med. 2023 Sep 1; 82 (3): 326335326-335.

AbstractOpioid use disorder and opioid overdose deaths are a major public health crisis, yet highly effective evidence-based treatments are available that reduce morbidity and mortality. One such treatment, buprenorphine, can be initiated in the emergency department (ED). Despite evidence of efficacy and effectiveness for ED-initiated buprenorphine, universal uptake remains elusive. On November 15 and 16, 2021, the National Institute on Drug Abuse Clinical Trials Network convened a meeting of partners, experts, and federal officers to identify research priorities and knowledge gaps for ED-initiated buprenorphine. Meeting participants identified research and knowledge gaps in 8 categories, including ED staff and peer-based interventions; out-of-hospital buprenorphine initiation; buprenorphine dosing and formulations; linkage to care; strategies for scaling ED-initiated buprenorphine; the effect of ancillary technology-based interventions; quality measures; and economic considerations. Additional research and implementation strategies are needed to enhance adoption into standard emergency care and improve patient outcomes.Copyright © 2023 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

38 keywords...

hide…